Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Strategic Master's Award - First Nations, Inuit and/or Métis Health

University of Alberta

$17,500.00

Evaluating the Therapeutic Potential of Antisense Oligonucleotides and CRISPR Activation in Spinal Bulbar Muscular Atrophy, with a Focus on its Prevalence in Canadian Indigenous Populations

FY 2023-24

Summary
Spinal bulbar muscular atrophy (SBMA) is a genetic disorder primarily affecting males, resulting from a mutation in the androgen receptor (AR) gene. SBMA manifests as progressive muscle weakness, coupled with challenges responding to male hormones. Patients with SBMA face difficulties with speech, swallowing, and mobility. My recent study revealed that the Indigenous population in Western Canada exhibits the highest global prevalence of SBMA. The lack of effective therapies underscores the critical need for viable treatment options. One approach involves using antisense oligonucleotides (ASOs) that target and mitigate the impact of disease-causing genes. In studies with mice with SBMA, these ASOs reduced AR expression in either the central nervous system (CNS) or peripheral tissues. SBMA affects both the CNS and peripheral tissues. Therefore, using a carrier capable of improving the delivery of ASOs to all affected sites holds the potential to enhance their efficacy. Another potential treatment involves an isoform of AR, known as AR2, that regulates AR activity. Increasing AR2 levels in mice with SBMA reduces the effects of dysfunctional AR. CRISPR activation (CRISPRa), an emerging therapeutic technique, binds to the start of a gene, increasing the production of its associated protein. For the treatment of SBMA, CRISPRa targeting AR2 is a promising approach. This study aims to assess the efficacy of different therapeutic strategies for SBMA treatment. ASOs targeting AR, with carriers that facilitate dual delivery to the CNS and peripheral tissues, and CRISPRa designed to increase AR2 levels, will be administered to male SBMA mice and cells from SBMA patients. The anticipated outcome is the identification of therapies with the potential to treat all patients with SBMA. To begin to address the health inequities that Indigenous people face is to meet the clinical needs of Indigenous people affected by SBMA through the translation of effective therapies to the clinic.
Program
CIHR Strategic Master's Award - First Nations, Inuit and/or Métis Health
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
498787
Name
Leckie Jamie N
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Indigenous Peoples' Health
Theme2
Biomedical
Prcname2
Master's Award: Strategic Master's Award
Projecttitle
Evaluating the Therapeutic Potential of Antisense Oligonucleotides and CRISPR Activation in Spinal Bulbar Muscular Atrophy, with a Focus on its Prevalence in Canadian Indigenous Populations
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
CIHR Strategic Master's Award - First Nations, Inuit and/or Métis Health
Keyworddelim
Androgen Receptor; Antisense Oligonucleotides; Ar Isoform 2; Crispr Activation; Spinal Bulbar Muscular Atrophy
Abstract
Spinal bulbar muscular atrophy (SBMA) is a genetic disorder primarily affecting males, resulting from a mutation in the androgen receptor (AR) gene. SBMA manifests as progressive muscle weakness, coupled with challenges responding to male hormones. Patients with SBMA face difficulties with speech, swallowing, and mobility. My recent study revealed that the Indigenous population in Western Canada exhibits the highest global prevalence of SBMA. The lack of effective therapies underscores the critical need for viable treatment options. One approach involves using antisense oligonucleotides (ASOs) that target and mitigate the impact of disease-causing genes. In studies with mice with SBMA, these ASOs reduced AR expression in either the central nervous system (CNS) or peripheral tissues. SBMA affects both the CNS and peripheral tissues. Therefore, using a carrier capable of improving the delivery of ASOs to all affected sites holds the potential to enhance their efficacy. Another potential treatment involves an isoform of AR, known as AR2, that regulates AR activity. Increasing AR2 levels in mice with SBMA reduces the effects of dysfunctional AR. CRISPR activation (CRISPRa), an emerging therapeutic technique, binds to the start of a gene, increasing the production of its associated protein. For the treatment of SBMA, CRISPRa targeting AR2 is a promising approach. This study aims to assess the efficacy of different therapeutic strategies for SBMA treatment. ASOs targeting AR, with carriers that facilitate dual delivery to the CNS and peripheral tissues, and CRISPRa designed to increase AR2 levels, will be administered to male SBMA mice and cells from SBMA patients. The anticipated outcome is the identification of therapies with the potential to treat all patients with SBMA. To begin to address the health inequities that Indigenous people face is to meet the clinical needs of Indigenous people affected by SBMA through the translation of effective therapies to the clinic.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leckie, Jamie N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~